Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting

Author's Avatar
Sep 15, 2019
Article's Main Image

Late-breaking results support Kodiak's objective of every three-, four-, and five-month long-interval dosing of KSI-301 in patients with wet AMD

KSI-301 continues towards its development goals of demonstrating safety and efficacy (with over 250 injections given to over 100 patients with no intraocular inflammation) and now promising durability data

PR Newswire